337 related articles for article (PubMed ID: 7883736)
1. Assessment of extrapyramidal symptoms during acute neuroleptic treatment.
Mazure CM; Cellar JS; Bowers MB; Nelson JC; Takeshita J; Zigun B
J Clin Psychiatry; 1995 Mar; 56(3):94-100. PubMed ID: 7883736
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute neuroleptic-induced movement disorders.
Tonda ME; Guthrie SK
Pharmacotherapy; 1994; 14(5):543-60. PubMed ID: 7997388
[TBL] [Abstract][Full Text] [Related]
3. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders.
Kim JH; Jung HY; Kang UG; Jeong SH; Ahn YM; Byun HJ; Ha KS; Kim YS
Mov Disord; 2002 Nov; 17(6):1354-9. PubMed ID: 12465082
[TBL] [Abstract][Full Text] [Related]
4. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():23-7. PubMed ID: 9766616
[TBL] [Abstract][Full Text] [Related]
5. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
6. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study.
Weiden PJ; Mann JJ; Haas G; Mattson M; Frances A
Am J Psychiatry; 1987 Sep; 144(9):1148-53. PubMed ID: 2888321
[TBL] [Abstract][Full Text] [Related]
7. Motor and mental aspects of acute extrapyramidal syndromes.
Casey DE
Acta Psychiatr Scand Suppl; 1994; 380():14-20. PubMed ID: 7914042
[TBL] [Abstract][Full Text] [Related]
8. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
[TBL] [Abstract][Full Text] [Related]
9. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Honer WG; Kopala LC; Rabinowitz J
J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
[TBL] [Abstract][Full Text] [Related]
10. Movement disorders associated with neuroleptic treatment.
Wirshing WC
J Clin Psychiatry; 2001; 62 Suppl 21():15-8. PubMed ID: 11584982
[TBL] [Abstract][Full Text] [Related]
11. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
Modestin J; Wehrli MV; Stephan PL; Agarwalla P
Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
[TBL] [Abstract][Full Text] [Related]
12. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
13. [Extrapyramidal effects of antipsychotic drugs].
Kulisevsky J; Otermin P
Neurologia; 2003 Jun; 18(5):262-8. PubMed ID: 12768512
[TBL] [Abstract][Full Text] [Related]
14. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.
Ghadirian AM; Annable L; Bélanger MC; Chouinard G
J Clin Psychiatry; 1996 Jan; 57(1):22-8. PubMed ID: 8543543
[TBL] [Abstract][Full Text] [Related]
15. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
[TBL] [Abstract][Full Text] [Related]
16. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group.
McManus DQ; Arvanitis LA; Kowalcyk BB
J Clin Psychiatry; 1999 May; 60(5):292-8. PubMed ID: 10362435
[TBL] [Abstract][Full Text] [Related]
17. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
Kinon BJ; Kane JM; Chakos M; Munne R
Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.
Ganzini L; Casey DE; Hoffman WF; McCall AL
Arch Intern Med; 1993 Jun; 153(12):1469-75. PubMed ID: 8512437
[TBL] [Abstract][Full Text] [Related]
19. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
20. Clozapine, negative symptoms, and extrapyramidal side effects.
Kane JM; Safferman AZ; Pollack S; Johns C; Szymanski S; Kronig M; Lieberman JA
J Clin Psychiatry; 1994 Sep; 55 Suppl B():74-7. PubMed ID: 7961579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
